V
Voyager Therapeutics, Inc. (VYGR)
3.96
0.00 (0.00%)
Get all premium features to the best stock analysis tool
3.96
0.00 (0.00%)
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer’s disease. The company also provides research program for the treatment of Huntington’s disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
| Name | Position |
|---|---|
| Dr. Alfred W. Sandrock Jr., M.D., Ph.D. | President, CEO & Director |
| Dr. Krystof Bankiewicz M.D., Ph.D. | Founder |
| Dr. Mark A. Kay M.D., Ph.D. | Founder |
| Mr. Todd Carter Ph.D. | Chief Scientific Officer |
| Ms. Robin Swartz | Chief Business Officer & COO |
| Ms. Trista Morrison | Chief Corporate Affairs Officer & Chief of Staff to the CEO |
| Date | Type | Document |
|---|---|---|
| 2026-03-09 | 10-K | vygr-20251231x10k.htm |
| 2026-01-08 | 8-K | tm262517d1_8k.htm |
| 2025-11-10 | S-3 | tm2530415-1_s3asr.htm |
| 2025-09-02 | 8-K | tm2524800d1_8k.htm |
| 2025-08-06 | 10-Q | vygr-20250630x10q.htm |
| 2025-06-09 | S-8 | tm2517216d1_s8.htm |
| 2025-06-05 | 8-K | tm2517216d2_8k.htm |
| 2025-05-06 | 10-Q | vygr-20250331x10q.htm |
| 2025-04-23 | ARS | vygr-20241231xars.pdf |
| 2025-03-11 | S-8 | tm258659d1_s8.htm |